Gilead Has 'Good News' But is it Enough?
Gilead Sciences' bictegravir suppressed HIV better than rival Glaxo's dolutegravir.
Gilead Science's (GILD) - Get Reportbictegravir paired with Gilead's TAF backbone suppressed HIV viral loads considered undetectable in 97% of newly diagnosed HIV patients, compared with 94% of patients in the study treated with Glaxo's (GSK) - Get Report dolutegravir. Though this is exciting news for Gilead's HIV franchise, it may not be enough to compensate for falling hepatitis C sales.
This article was written by a staff member of TheStreet.
